[Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003616
German
Original Title:
Ivacaftor (Kombination mit Tezacaftor/Ivacaftor; zystische Fibrose, ab 12 Jahre, F508del-Mutation, homozygot)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a19-70.html
Year Published:
2019
URL for published report:
https://www.iqwig.de/download/A19-70_Ivacaftor_Nutzenbewertung-35a-SGB-V_V1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Cystic Fibrosis
- Adolescent
- Adult
- Chloride Channel Agonists
- Drug Therapy, Combination
- Quinolones
Keywords
- Ivacaftor
- Tezacaftor
- Cystic Fibrosis
- Child
- Adolescent
- Adult
- Benefit Assessment
- NCT01807923
- NCT01807949
- NCT02347657
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.